The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA.
Ali TafazzoliScott D RamseyAlissa ShaulAmeya ChavanWeicheng YeAnuraag R KansalJosh OfmanA Mark FendrickPublished in: PharmacoEconomics (2022)
An MCED test with high specificity would potentially improve long-term health outcomes and reduce cancer treatment costs, resulting in a value-based price of $1196 at a $100,000/quality-adjusted life-year willingness-to-pay threshold.